Orthocell Ltd ( (AU:OCC) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orthocell Ltd’s stock is on the rise following the company’s first US sales revenue for its Remplir™ nerve repair product. This milestone, achieved shortly after FDA clearance, underscores Orthocell’s strategic use of specialist distributors and logistics partners. Analysts are optimistic, assigning a Buy rating and setting a price target of A$1.32, fueled by the potential for growth in the $1.6 billion US nerve repair market. The company’s initiatives to engage US surgeons and increase product awareness are further enhancing market confidence.
More about Orthocell Ltd
YTD Price Performance: -9.93%
Average Trading Volume: 1,139,323
Technical Sentiment Signal: Buy
Current Market Cap: A$317.6M
For further insights into OCC stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.